Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Rituximab may help patients with aPL-related clinical problems

Rituximab may help patients with aPL-related clinical problems

Gabrielle's Angel Foundation announces recipients of new collaborative grants for cancer research

Gabrielle's Angel Foundation announces recipients of new collaborative grants for cancer research

No advantage of continuous over bolus doxorubicin in ALL children

No advantage of continuous over bolus doxorubicin in ALL children

Tanshinones protect against sepsis: Study

Tanshinones protect against sepsis: Study

Feinstein seeks NDA approval for Fluorodopa F 18 PET scan to diagnose parkinsonian syndromes

Feinstein seeks NDA approval for Fluorodopa F 18 PET scan to diagnose parkinsonian syndromes

Adding bortezomib ‘boosts acute myeloid leukemia chemotherapy response’

Adding bortezomib ‘boosts acute myeloid leukemia chemotherapy response’

Study reveals increased risk of leukemia among Chernobyl cleanup workers

Study reveals increased risk of leukemia among Chernobyl cleanup workers

Destruction of newborn screening left over samples may be detrimental to medical research

Destruction of newborn screening left over samples may be detrimental to medical research

Carbohydrate-rich food intake may cause recurrence of colon cancer

Carbohydrate-rich food intake may cause recurrence of colon cancer

Synta announces interim results from docetaxel Phase 2b/3 trial on NSCLC

Synta announces interim results from docetaxel Phase 2b/3 trial on NSCLC

Ion AmpliSeq Community Panels from Life Technologies

Ion AmpliSeq Community Panels from Life Technologies

Sapacitabine tolerated, efficacious in elderly leukemia patients

Sapacitabine tolerated, efficacious in elderly leukemia patients

CIBMTR renews Stem Cell Therapeutics Outcomes Database contract with HRSA

CIBMTR renews Stem Cell Therapeutics Outcomes Database contract with HRSA

Imatinib mesylate effectively treats children with neurofibromatosis type 1 tumors

Imatinib mesylate effectively treats children with neurofibromatosis type 1 tumors

Multiple sclerosis disease activity reduced by leukaemia drug, even when first-line treatment has failed

Multiple sclerosis disease activity reduced by leukaemia drug, even when first-line treatment has failed

Pins made of single atoms to fight cancer

Pins made of single atoms to fight cancer

Study identifies new prognostic biomarker and therapeutic target for adult B-ALL

Study identifies new prognostic biomarker and therapeutic target for adult B-ALL

Immigration status, language of caregivers appear to impact care of Hispanic children with cancer

Immigration status, language of caregivers appear to impact care of Hispanic children with cancer

Researchers decode software instructions that drive 3 different forms of acute lymphoblastic leukemia

Researchers decode software instructions that drive 3 different forms of acute lymphoblastic leukemia

Scientists decode epigenetic programming of three virulent forms of acute lymphoblastic leukemia

Scientists decode epigenetic programming of three virulent forms of acute lymphoblastic leukemia

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.